



NEWS RELEASE
For Immediate Release

**PERCEPTRONIX APPOINTS DR. BOJANA TURIC AS PRESIDENT
AND CHIEF EXECUTIVE OFFICER**

Vancouver, Canada (April 24, 2007) – Perceptronix Medical Inc. (“Perceptronix”) announced today that Mr. Carl Roy has resigned as President and Chief Executive Officer, effective immediately. The Board of Directors has appointed Dr. Bojana Turic, MD, Vice President and Chief Operating Officer of Perceptronix, as President and Chief Executive Officer, effectively immediately.

“We would like to thank Mr. Roy for his contribution during a period of significant change in our company”, said Board Chairman Milton Wong. “We are very pleased that Dr. Turic has accepted the role of CEO and we look forward to working with her in the continued commercialization of Perceptronix’s innovative early cancer detection and diagnostic products and services in Canada, the US, and EU.”

As one of the senior scientists employed by Perceptronix when it was founded as a spin off of the BC Cancer Agency in June 1999, Dr. Turic has led Perceptronix through significant clinical and regulatory milestones including, positioning the company as a world leader in early cancer diagnostic technologies, the development of strategic commercialization alliances, and execution of the company’s first commercial agreements.

“I welcome the opportunity to work with the Board of Directors and the senior management team to achieve Perceptronix’s goal of providing physicians with increased options for prolonging and improving the quality of patient’s lives”, said Dr. Turic.

About Perceptronix Medical Inc. (www.perceptronix.com)

Perceptronix Medical Inc. (founded in 1999) is a private cancer diagnostics company based in Vancouver, Canada. Perceptronix commercializes early cancer detection technologies developed in partnership with the BC Cancer Agency, a world-leader in cancer care and research, with a particularly notable track record in pioneering early cancer detection programs.

This news release is not, and under no circumstances, to be construed as, an advertisement, solicitation or offering of securities of Perceptronix Medical Inc. The statements made in this news release may contain certain forward-looking statements that involve a number of risks and uncertainties. Actual events or results may differ from the Company's expectations.

-30-

Contact:

Dr. Milton Wong
Chairman, Board of Directors
Phone: 604-257-4882

Media Contact:

Amanda Smith, BSc
Smith Biotech
Phone: 778-846-4116